Advertisement

Topics

Alkermes Announces Positive Preliminary Topline Results From Phase III Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia

20:00 EDT 29 Jun 2017 | BioSpace

Once-Daily, Oral Product Candidate Demonstrated Antipsychotic Efficacy Statistically Superior to Placebo and Similar to Olanzapine in ENLIGHTEN-1 Study Management to Hold Conference Call Today at 4:30 p.m. ET DUBLIN--(

Original Article: Alkermes Announces Positive Preliminary Topline Results From Phase III Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia

NEXT ARTICLE

More From BioPortfolio on "Alkermes Announces Positive Preliminary Topline Results From Phase III Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia"

Advertisement
Quick Search
Advertisement
Advertisement